Loading…
Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin‐like and a hydroxyproline‐rich domain
ABSTRACT In late summer, pollen grains originating from Compositae weeds (e.g., mugwort, ragweed) are a major source of allergens worldwide. Here, we report the isolation of a cDNA clone coding for Art v 1, the major allergen of mugwort pollen. Sequence analysis showed that Art v 1 is a secreted all...
Saved in:
Published in: | The FASEB journal 2003-01, Vol.17 (1), p.106-108 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
In late summer, pollen grains originating from Compositae weeds (e.g., mugwort, ragweed) are a major source of allergens worldwide. Here, we report the isolation of a cDNA clone coding for Art v 1, the major allergen of mugwort pollen. Sequence analysis showed that Art v 1 is a secreted allergen with an N‐terminal cysteine‐rich domain homologous to plant defensins and a C‐terminal proline‐rich region containing several (Ser/Ala)(Pro)2–4 repeats. Structural analysis showed that some of the proline residues in the C‐terminal domain of Art v 1 are posttranslationally modified by hydroxylation and O‐glycosylation. The O‐glycans are composed of 3 galactoses and 9–16 arabinoses linked to a hydroxyproline and represent a new type of plant O‐glycan. A 3‐D structural model of Art v 1 was generated showing a characteristic “head and tail” structure. Evaluation of the antibody binding properties of natural and recombinant Art v 1 produced in Escherichia coli revealed the involvement of the defensin fold and posttranslational modifications in the formation of epitopes recognized by IgE antibodies from allergic patients. However, posttranslational modifications did not influence T‐cell recognition. Thus, recombinant nonglycosylated Art v 1 is a good starting template for engineering hypoallergenic vaccines for weed‐pollen therapy. |
---|---|
ISSN: | 0892-6638 1530-6860 |
DOI: | 10.1096/fj.02-0472fje |